You are about to leave the website of Otsuka Novel Products GmbH and view the content of an external website. Otsuka Novel Products GmbH cannot be held responsible for the content of external websites.
Bacteria can become resistant to any antibiotic due to inappropriate treatment, such as when it is interrupted or the medicine is used inappropriately.2 Apart When the TB bacteria becomes resistant to at least isoniazid and rifampicin— the two most common anti-TB medicines—it is called MDR-TB.1
Otsuka has had a TB medicine discovery programme for over 40 years and has been a recognised leader in TB research through its commitment to the development of new TB compounds as well as the building of a clinical infrastructure within developing countries affected by the disease.
One of the compounds developed by Otsuka has received regulatory approval for treatment of adults with pulmonary MDR-TB as one of first TB medicines in about 50 years.4 Apart from continuing its research and development programme, Otsuka is also engaging in multiple third-party collaborations looking at shorter, more effective and more patient-friendly ways to fight MDR-TB.
1. World Health Organization. Global Tuberculosis Report 2016. World Health Organization, Geneva, 2016.
2. World Health Organization. Tuberculosis Factsheet 104. Reviewed March 2017. Available at: http://www.who.int/mediacentre/factsheets/fs104/en/ (Accessed 19 June 2017).
3. By the end of 2015, XDR-TB had been reported by 117 countries.
4. Gualano G., et al. New Antituberculosis Drugs: From Clinical Trial to Programmatic Use. Infect Dis Rep. 2016; 8(2): 6569.
Information current as of 26-06-2017